Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is the same. Opioid crisis hit. Many doctors moved away from prescribing OxyContin due to the legal risks and ramifications. The market tanked. Plus, we’re seeing other options (e.g., cannabis) to help manage pain.
I think this filing is moot. I think Purdue would have pursued litigation otherwise as they did with Accord if Elite was leading the way.
Elite filed it long ago, but all were dropped due to added insufflation study requirement. All had to complete this and refile.
At end of the day, all will get launched. It’s just a matter of timing of a few months here or there.
I don’t lose sleep over it. To each their own.
That was when we were a contract manufacturer. Margins were slimmer. How times have changed for sure.
This is the same for all the others we recently re-acquired. They are no longer discontinued, but shifted to active status.
What do you mean? Methadone is already listed in Orange book under Elite like Codeine, Perc & Norco, as expected, but will launch in time. I believe it was last to be launched based on last cc.
Facility expansion and equipment are depreciated over life of asset and R&D is expensed in P&L.
I believe he meant yes the incremental $75M was for Norco/Perc/Methadone.
10% was just Vyvanse with shrinking market. Would not have included Concerta. Until we see a BE and filing acceptance let’s not factor that unknown in. Concerta has been a hard nut to crack for manufacturers. This is only way math makes sense.
If Vyvanse is approved and Concerta gets positive BE, that’s all we’ll need to get there and stay there. Plus, we have Perc, Norco and methadone as icing on the cake.
DEA approval should be coming soon, if it hasn’t already been received.
That has to do with the history of Mikah and the ongoing non-arms length relationship. Do your dd and then make up your own mind. I’m not a fan of it and hoping Elite buys out Mikah’s ownership of Adderall soon.
Yes, website has same issue.
Do you only post info from chat GPT?
“Put all your eggs in the one basket and watch that basket.”
- Warren Buffett
Yes, but these aren’t happening very near term. Codeine still has about month to go before launch if they follow 6-8 week path previously communicated. Vigabatrin can likely be scratched from list.
What good news is that? Codeine won’t be launched until mid-October. BE results?
Saw that too. Of course it’s overbought based on historical trading data. It’s backwards looking.
“Although the side effects of the drug are a rarity, study lead author Lauren Moran said doctors who prescribe these stimulants for attention-deficit/hyperactivity disorder should "maybe stay away from (higher) doses, or just make sure that you're carefully monitoring patients."
Nina Kraguljac, a professor of psychiatry and behavioral health at Ohio State University, said the study clarifies that only higher doses of Adderall and other prescription amphetamines are linked to higher risk.
"That is absolutely novel, very clinically relevant and very helpful because it also assures you don't necessarily increase your psychosis risk by taking lower to medium doses," Kraguljac said.
I see ASCM as top Bid & Ask
I thought it was already sold to them as part of the deal and we simply played a temporary role as mfr, if launch took place in time before contract expires.
*Nasrat lol
Voice to text doesn’t like his name.
Master could easily throw in another poison pill
All depends when you bought. Fun to watch for sure. Less than a month away until codeine w/ APAP launch paving way for Percocet & Norco.
Vyvanse will solidify it along with known pipeline we are launching.
Uplisting to an exchange with R/S to clean up O/S with growing revenues and profitable will attract institutional investors. Nasrat would have to go to investor conferences and actually have an outreach/IR strategy, but that comes with the public company territory. It would be an absolutely huge win. Not only do you attract institutional investors, but also index funds.
Fun fact: most shares today are held by passive investment vehicles (indexed funds like Blackrock, Vanguard, etc). Been this way for almost 10 years. How much does Elite get of that today? None.
I am expecting a R/S near term after Vyvanse approval with follow suite of uplist and then acquisition within 2 years.
Come on dude. With a 200 forward multiple? We’re all excited for what’s to come, but no realistic analytics and math will come to a current $7 billion valuation.
I think once Vyvanse is approved, launched and capturing market share we will get there with current known portfolio.
Loving the nice volume in these trading sessions over the past couple of weeks. Eager to see who is buying in.
No, I don’t think so. I don’t think Elite is out of the woods yet. We’re still waiting on FDA anyways before we can move forward.
Not sure they have the cash available. I would prefer not to sell out to slimy Purdue.
Cash flow doesn’t hit bottom line in P&L, only cash flow statement. Are you referring to R&D and not equipment? Most R&D is likely expensed.
I think you mean cash flow. Equipment is expensed via depreciation over the expected life (likely 10 years) so you’ll see D&A increase from here on out every quarter in three P&L until fully depreciated.
Doubtful without a decent buyback, which can be initiated over time, but if we have a 2-year horizon or less, they might be able to get another 1 or 2 approved by FDA and launched. We’re still waiting on bioequivalency studies + few months of prep + 10 months review + prep to launch. That’s over a year from the BE positive results. Time is ticking…
Jim Cramer would say stay away from any OTC stock.
Not sure I’d label the methotrexate market as significant for Elite, but it is incremental to current state and that will continue to move us in the right direction.
That equates to $1.75B with 20% flow through to net profit using today’s financials. Being early to market will yield higher pricing, but not that good. As of now there is no path to that type of top line target.
I don’t think so. The run would have occurred closer to the timing of the valuation and would have stayed there. I don’t think the valuation played any role.